Better Med Spa’s Fat Burning Support program uses AOD‑9604, a synthetic fragment of human growth hormone that targets fat metabolism pathways to support lipolysis and limit new fat storage, especially when combined with diet and exercise. Because AOD‑9604 is not FDA‑approved and cannot be compounded under current guidance, it is offered only under a strict informed consent framework with full transparency about its investigational status, potential risks, and mixed efficacy data.
.png)
AOD‑9604 is a modified fragment of the C‑terminal region of human growth hormone (amino acids 177–191) that appears to mimic GH’s effects on fat metabolism without significantly affecting IGF‑1 or overall growth hormone levels. Preclinical and early human data suggest it may promote lipolysis, inhibit lipogenesis, and preferentially act on adipose tissue by influencing beta‑3 adrenergic–mediated pathways and hormone‑sensitive lipase activity. However, large obesity trials did not show clinically meaningful weight loss, and regulators have raised concerns about immunogenicity and safety data gaps, which is why Better Med Spa restricts its use to clearly informed, highly selected clients.
Our AOD-9604 peptides are designed to target:
AOD-9604 is believed to help with:
Experience the best in aesthetic and wellness care at Better Med Spa. Our personalized treatments are tailored to you, designed to help you look and feel your absolute best with confidence and ease.
We're here to answer your questions and provide the best services for your needs.
AOD‑9604 is a synthetic fragment of human growth hormone designed to influence fat metabolism, whereas GLP‑1 medications like Semaglutide act on gut and brain hormone pathways to reduce appetite and improve blood sugar. AOD‑9604 does not meaningfully increase GH or IGF‑1 levels and is considered a modest, mechanistic fat‑support peptide rather than a cornerstone obesity treatment.
No. AOD‑9604 is not FDA‑approved for any medical indication, and FDA advisory documents note concerns about immunogenicity, peptide-related impurities, and lack of sufficient safety and efficacy data. Better Med Spa offers Fat Burning Support only under a non‑FDA–approved informed consent model that clearly explains this status and presents it as an optional adjunct, not a standard-of-care obesity therapy.
Early and smaller studies suggested effects on fat metabolism and body fat distribution, but larger obesity trials did not show a robust, clinically meaningful weight loss outcome on their own. At Better Med Spa, AOD‑9604 is framed as a potential “nudge” for fat metabolism that only makes sense when layered onto disciplined nutrition, movement, and sometimes GLP‑1 or other medical therapies.
Reported side effects are typically mild—such as injection-site irritation, headache, or fatigue—but regulatory reviews highlight potential immunogenicity and uncertainties around long-term safety and product quality in compounded or non‑approved forms. For that reason, Better Med Spa uses strict sourcing standards, dosing protocols, and informed consent, and may not recommend AOD‑9604 for clients with autoimmune conditions or high risk tolerance concerns.
Fat Burning Support is positioned as an add‑on for motivated clients who are already in structured weight-loss or body-contouring programs and want every safe, transparent tool available. It can be paired with GLP‑1s, Tesamorelin, Sleep & Sculpt, IV metabolic support, and K‑Beauty–inspired facials and body treatments, with memberships and follow-ups designed to track progress, adjust protocols, and protect long-term health and trust.